DoriNano, Inc.

DoriNano, Inc. is a biotechnology company focused on developing advanced nanomedicine platforms based on DNA origami technology. The company utilizes DNA as a structural material to engineer 3D delivery vehicles that provide precise, nanoscale control over the spacing and stoichiometry of therapeutic payloads. This approach allows for the programmable design of drug delivery systems, offering benefits such as enhanced stability, versatile cargo conjugation, high drug loading capacity, and reduced immunogenicity compared to traditional nanoparticle delivery methods. The core technology originated from research conducted at the Dana-Farber Cancer Institute and the Wyss Institute at Harvard University.

By enabling the precise placement of drug combinations, DoriNano aims to significantly improve treatment efficacy for serious diseases, including cancer. Preclinical studies have demonstrated that the specific nanoscale arrangement of biological payloads can increase receptor binding affinity and downstream biological activity, potentially reducing required dosages by 10-100 fold. The company is initially applying this platform to the development of cancer vaccines, such as its DoriVac program for head and neck squamous cell carcinoma, and has entered into research collaborations to further expand the reach of its therapeutic delivery innovations.